Comprehensive Elucidation of Immunopathogenic Cascades, Astrocytopathy, and Complement-Mediated Neuroinflammation in Neuromyelitis Optica Spectrum Disorder: Integrating Molecular Biomarkers, Advanced Neuroimaging, and Emerging Monoclonal Antibody-Based Therapeutic Strategies

Neuromyelitis optica spectrum disorder (NMOSD) is a severe, relapsing autoimmune disease of the central nervous system characterized predominantly by immune-mediated injury to astrocytes, leading to secondary demyelination and neuronal damage. Unlike multiple sclerosis, which primarily targets myelin, NMOSD is now recognized as a prototypical autoimmune astrocytopathy, driven largely by pathogenic immunoglobulin G (IgG) autoantibodies directed against aquaporin-4 (AQP4), the principal water channel expressed on astrocytic endfeet (Lennon et al., 2004; Papadopoulos & Verkman, 2012). Binding of AQP4-IgG initiates complement activation, inflammatory cell recruitment, and astrocytic destruction, thereby disrupting blood–brain barrier (BBB) integrity and propagating neuroinflammation (Lucchinetti et al., 2014). This astrocyte-centric pathology distinguishes NMOSD from other demyelinating disorders and underscores its unique immunopathogenic basis.

Historically, NMOSD was first described in the late 19th century by Eugène Devic and Fernand Gault as a monophasic syndrome consisting of simultaneous optic neuritis and acute myelitis, termed Devic’s disease (Jarius & Wildemann, 2010). For decades, it was considered a variant of multiple sclerosis; however, the discovery of AQP4-IgG by Lennon and colleagues in 2004 revolutionized the understanding of the disease, establishing NMOSD as a distinct nosological entity (Lennon et al., 2004). Subsequent clinical and immunological insights expanded the disease concept to include a broader spectrum of presentations beyond the classical optic–spinal phenotype. This led to the formulation of revised diagnostic criteria by the International Panel for NMO Diagnosis (IPND), which formally introduced the term neuromyelitis optica spectrum disorder, encompassing both AQP4-IgG seropositive and seronegative cases with diverse core clinical characteristics (Wingerchuk et al., 2015).

Epidemiologically, NMOSD is a rare disorder but carries a substantial global health burden due to its severe disability and high relapse rate. The estimated prevalence ranges from approximately 0.5 to 10 per 100,000 individuals, with notable geographic and ethnic variability (Hor et al., 2020). Higher prevalence rates have been reported among Asian, African, and Latin American populations compared to Caucasian populations (Pandit et al., 2015). NMOSD exhibits a strong female predominance, particularly in AQP4-IgG seropositive patients, with female-to-male ratios reaching up to 9:1 (Wingerchuk et al., 2015). The disease often manifests in adulthood, although pediatric and late-onset cases are increasingly recognized. Despite its rarity, NMOSD contributes significantly to neurological disability due to frequent relapses, cumulative neurological damage, and incomplete recovery following attacks (Mealy et al., 2012).

Clinically, NMOSD is defined by a constellation of core phenotypes, most prominently optic neuritis and longitudinally extensive transverse myelitis (LETM). Optic neuritis in NMOSD is typically severe, often bilateral, and associated with poor visual recovery, reflecting extensive astrocytic and axonal injury within the optic nerves (Petzold et al., 2014). LETM is characterized by spinal cord lesions extending over three or more contiguous vertebral segments, leading to profound motor, sensory, and autonomic dysfunction (Wingerchuk et al., 2015). In addition to these classical features, NMOSD may involve other regions rich in AQP4 expression, including the area postrema (causing intractable nausea, vomiting, and hiccups), brainstem, diencephalon, and cerebral hemispheres (Apiwattanakul et al., 2010). The heterogeneity of clinical presentations reflects the widespread distribution of astrocytic AQP4 channels and highlights the systemic nature of astrocytopathy in NMOSD.

Despite significant advances in understanding NMOSD pathogenesis, there remains a critical need for integrated mechanistic and therapeutic approaches. The identification of AQP4-IgG has enabled more accurate diagnosis and targeted treatment strategies; however, challenges persist, including disease heterogeneity, seronegative cases, and variable treatment responses. Furthermore, emerging insights into complement-mediated neuroinflammation, B-cell dysregulation, and cytokine networks—particularly interleukin-6 (IL-6)—have paved the way for novel monoclonal antibody therapies (Cree et al., 2019; Yamamura et al., 2019). Integrating molecular biomarkers, advanced neuroimaging modalities, and targeted immunotherapies is essential for improving diagnostic precision, predicting disease activity, and optimizing individualized treatment strategies. A comprehensive understanding of these interconnected domains is therefore crucial for advancing clinical outcomes and reducing the long-term burden of NMOSD.

2. Immunopathogenic Cascades in Neuromyelitis Optica Spectrum Disorder (NMOSD)

The immunopathogenesis of NMOSD is a highly orchestrated, multi-step process involving breakdown of immune tolerance, dysregulated humoral and cellular immune responses, and subsequent disruption of the blood–brain barrier (BBB), culminating in astrocyte-targeted injury. Central to this cascade is the production of pathogenic aquaporin-4 immunoglobulin G (AQP4-IgG), which drives complement-mediated astrocytopathy and neuroinflammation (Lennon et al., 2004; Lucchinetti et al., 2014). The following sections delineate the key mechanistic components underlying NMOSD pathogenesis.

2.1 Loss of Immune Tolerance

Genetic Susceptibility (HLA Associations)

Genetic predisposition plays a pivotal role in NMOSD susceptibility, particularly through associations with specific human leukocyte antigen (HLA) alleles. Studies have demonstrated strong correlations between NMOSD and HLA class II alleles such as HLA-DRB1*03:01, HLA-DPB1*05:01, and HLA-DRB1*16:02, which are implicated in antigen presentation and autoreactive T-cell activation (Pandit et al., 2015; Kim et al., 2010). These alleles facilitate the presentation of AQP4-derived peptides to CD4+ T cells, thereby promoting a breakdown in central and peripheral tolerance. The genetic architecture also overlaps with other autoimmune diseases, suggesting shared immunogenetic pathways.

Environmental Triggers (Viral Infections and Microbiome Dysbiosis)

Environmental factors further contribute to immune dysregulation. Viral infections, including Epstein–Barr virus (EBV) and varicella-zoster virus (VZV), have been proposed as triggers via mechanisms such as molecular mimicry and bystander activation (Levin et al., 2010). Additionally, emerging evidence highlights the role of gut microbiome dysbiosis in modulating immune responses in NMOSD. Alterations in microbial composition, particularly increased abundance of pro-inflammatory taxa such as Clostridium perfringens, may promote Th17 polarization and enhance autoimmunity (Cree et al., 2016). These environmental factors synergize with genetic predisposition to initiate loss of immune tolerance.

2.2 Role of B Cells and Plasma Cells

AQP4-IgG Production

B cells are central effectors in NMOSD pathogenesis through their differentiation into plasma cells that produce AQP4-IgG. These autoantibodies are predominantly of the IgG1 subclass, capable of activating the classical complement pathway (Lennon et al., 2004). The production of AQP4-IgG occurs primarily in peripheral lymphoid tissues, supported by T-cell help and cytokines such as interleukin-6 (IL-6), which promotes plasmablast survival and differentiation (Chihara et al., 2011).

Peripheral vs CNS Immune Activation

Although AQP4-IgG is generated peripherally, its pathogenic effects manifest within the central nervous system (CNS) upon crossing the BBB. Peripheral immune activation precedes CNS infiltration, with circulating plasmablasts and memory B cells playing a critical role in disease relapses (Bennett et al., 2009). Intrathecal synthesis of AQP4-IgG is minimal, distinguishing NMOSD from multiple sclerosis and reinforcing the importance of systemic immunity.

Plasmablast Expansion

A hallmark feature of NMOSD is the expansion of circulating CD19+CD27++CD38++ plasmablasts, particularly during relapses. These cells exhibit high expression of IL-6 receptors and produce large quantities of AQP4-IgG (Chihara et al., 2011). Their frequency correlates with disease activity, making them a potential biomarker and therapeutic target.

2.3 T Cell-Mediated Modulation

Th17 and Th1 Polarization

CD4+ T helper cells play a crucial modulatory role in NMOSD. Th17 cells, characterized by the secretion of IL-17, IL-21, and IL-22, are significantly elevated in NMOSD patients and contribute to BBB disruption and recruitment of neutrophils (Korn et al., 2009). Th1 cells, producing interferon-gamma (IFN-γ), also participate in pro-inflammatory signaling and macrophage activation. The Th17/Th1 axis synergistically amplifies inflammation and supports B-cell-mediated autoimmunity.

Regulatory T-Cell Dysfunction

Regulatory T cells (Tregs), which normally maintain immune tolerance, are functionally impaired in NMOSD. Reduced suppressive capacity and altered cytokine profiles of Tregs contribute to unchecked autoreactive immune responses (Venken et al., 2010). This imbalance between effector T cells and Tregs further exacerbates disease progression.

2.4 Blood–Brain Barrier (BBB) Disruption

Endothelial Activation

BBB integrity is compromised early in NMOSD pathogenesis. Pro-inflammatory cytokines such as IL-6 and TNF-α induce endothelial activation, upregulating adhesion molecules (ICAM-1, VCAM-1) that facilitate leukocyte transmigration into the CNS (Abboud & Probasco, 2019). Activated endothelial cells also produce chemokines that attract immune cells to sites of inflammation.

Cytokine-Mediated Permeability Changes

Cytokines play a central role in increasing BBB permeability. IL-17 and IL-6 disrupt tight junction proteins (e.g., claudins, occludins), leading to enhanced paracellular leakage (Kebir et al., 2007). This allows circulating AQP4-IgG and immune cells to access astrocytic targets within the CNS. Once inside  the CNS, AQP4-IgG binds to astrocytes, initiating complement activation and downstream neuroinflammatory cascades.

Table 1. Key Immunopathogenic Mechanisms in NMOSD

Figure 1. Immunopathogenic Cascade in NMOSD

3. Astrocytopathy in Neuromyelitis Optica Spectrum Disorder (NMOSD)

Astrocytopathy represents the defining pathological hallmark of NMOSD, distinguishing it from classical demyelinating disorders. In NMOSD, astrocytes are the primary cellular targets, with injury driven predominantly by pathogenic aquaporin-4 immunoglobulin G (AQP4-IgG). This astrocyte-directed immune attack initiates a cascade of inflammatory and neurodegenerative processes, ultimately leading to demyelination, axonal injury, and neurological disability (Papadopoulos & Verkman, 2012; Lucchinetti et al., 2014).

3.1 Aquaporin-4 (AQP4) as a Central Target

Distribution of AQP4 in Astrocytic Endfeet

Aquaporin-4 (AQP4) is the most abundant water channel in the central nervous system (CNS), predominantly expressed on the astrocytic endfeet that ensheath cerebral microvessels, ependymal surfaces, and the glia limitans. This polarized distribution enables astrocytes to regulate water homeostasis, maintain ionic balance, and support blood–brain barrier (BBB) integrity (Nielsen et al., 1997; Papadopoulos & Verkman, 2012). High-density AQP4 expression is observed in regions commonly affected in NMOSD, including the optic nerves, spinal cord, area postrema, and periventricular regions, explaining the characteristic lesion distribution in this disease.

Binding of AQP4-IgG

The discovery of AQP4-IgG autoantibodies established the molecular basis of NMOSD. These IgG1 subclass antibodies selectively bind to extracellular epitopes of AQP4 arranged in orthogonal arrays of particles (OAPs) on astrocyte membranes (Lennon et al., 2004). Upon binding, AQP4-IgG triggers complement activation and recruits immune effector cells, leading to targeted astrocytic injury. Importantly, the pathogenicity of AQP4-IgG has been demonstrated in both in vitro and in vivo models, confirming its central role in disease initiation (Hinson et al., 2007).

3.2 Mechanisms of Astrocyte Injury

Astrocyte damage in NMOSD occurs through two main immune-mediated mechanisms: antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Antibody-Dependent Cellular Cytotoxicity (ADCC)

In ADCC, AQP4-IgG-coated astrocytes are recognized by immune effector cells such as natural killer (NK) cells, macrophages, and neutrophils via Fc gamma receptors (FcγRs). This interaction leads to the release of cytotoxic mediators, including perforin, granzymes, and reactive oxygen species, resulting in astrocyte apoptosis and necrosis (Ratelade et al., 2013). Neutrophils and eosinophils, which are prominently observed in NMOSD lesions, further amplify tissue injury through degranulation and protease release.

Complement-Dependent Cytotoxicity (CDC)

CDC is a main mechanism underlying astrocyte destruction in NMOSD. Binding of AQP4-IgG activates the classical complement pathway through C1q, leading to a cascade involving C3 and C5 cleavage and culminating in the formation of the membrane attack complex (MAC; C5b-9) (Lucchinetti et al., 2014). The insertion of MAC into astrocyte membranes results in osmotic lysis and cell death. Complement activation also generates anaphylatoxins (C3a, C5a), which recruit inflammatory cells and exacerbate neuroinflammation.

3.3 Secondary Effects of Astrocyte Loss

The destruction of astrocytes initiates a series of secondary pathological events that extend beyond astrocytic injury, affecting multiple cellular components of the CNS.

Glutamate Excitotoxicity

Astrocytes play a crucial role in glutamate clearance via excitatory amino acid transporters (EAATs), particularly EAAT2. Loss of astrocytic function leads to impaired glutamate uptake, resulting in extracellular glutamate accumulation and excitotoxic neuronal injury (Hinson et al., 2008). Excess glutamate overstimulates NMDA receptors on neurons and oligodendrocytes, leading to calcium influx, oxidative stress, and cell death.

Oligodendrocyte Damage and Demyelination

Although oligodendrocytes are not the main targets in NMOSD, they undergo secondary injury due to astrocyte loss and inflammatory milieu. Disruption of astrocyte–oligodendrocyte metabolic coupling impairs myelin maintenance, leading to secondary demyelination (Papadopoulos & Verkman, 2012). Additionally, complement activation and inflammatory cytokines further damage oligodendrocytes, contributing to lesion progression.

Neuronal Degeneration

Neuronal injury in NMOSD is a downstream consequence of astrocyte destruction, excitotoxicity, and inflammatory damage. Axonal loss is prominent in spinal cord and optic nerve lesions, correlating with irreversible neurological deficits such as paralysis and vision loss (Wingerchuk et al., 2015). Neurodegeneration is further exacerbated by mitochondrial dysfunction, oxidative stress, and impaired trophic support from astrocytes.

Table 2. Mechanisms of Astrocyte Injury and Secondary Pathology in NMOSD

Figure 2. Astrocytopathy and Downstream Neurodegeneration in NMOSD

4. Complement-Mediated Neuroinflammation in Neuromyelitis Optica Spectrum Disorder (NMOSD)

Complement-mediated neuroinflammation constitutes a central effector mechanism in NMOSD pathogenesis, linking AQP4-IgG binding to astrocyte destruction and widespread inflammatory injury. The activation of the complement cascade not only induces direct cytotoxicity via membrane attack complex (MAC) formation but also amplifies immune responses through recruitment of inflammatory cells and cytokine release (Lucchinetti et al., 2014; Papadopoulos & Verkman, 2012). This section delineates the molecular pathways and downstream consequences of complement activation in NMOSD.

4.1 Activation Pathways

Classical Complement Pathway via AQP4-IgG

The complement system in NMOSD is primarily activated through the classical pathway, initiated by the binding of AQP4-IgG (IgG1 subclass) to aquaporin-4 on astrocyte membranes. This antigen–antibody complex recruits the complement protein C1q, which triggers a proteolytic cascade involving sequential activation of C1r and C1s (Lennon et al., 2004; Lucchinetti et al., 2014). This leads to cleavage of complement components C4 and C2, forming the C3 convertase (C4b2a), which amplifies the cascade.

Role of C1q, C3, and C5

• C1q: Serves as the initiating molecule that recognizes AQP4-IgG-bound astrocytes, marking them for immune attack.
• C3: Central amplification component; cleavage into C3a and C3b enhances opsonization and inflammatory signaling.
• C5: Cleavage into C5a and C5b is pivotal; C5a acts as a potent anaphylatoxin and chemoattractant, while C5b initiates MAC formation (Ricklin et al., 2016).

The amplification loop ensures rapid escalation of complement activity, leading to extensive astrocytic damage.

4.2 Formation of Membrane Attack Complex (MAC)

Astrocyte Lysis

The terminal step of complement activation involves assembly of the membrane attack complex (MAC; C5b-9) on astrocyte membranes. MAC forms transmembrane pores that disrupt cellular integrity, causing osmotic imbalance, ion dysregulation, and ultimately astrocyte lysis (Hinson et al., 2007). Histopathological studies of NMOSD lesions consistently demonstrate deposition of complement components, including C9neo antigen, confirming active MAC-mediated injury (Lucchinetti et al., 2014).

Amplification of Inflammatory Cascades

Beyond direct cytotoxicity, MAC and upstream complement fragments amplify inflammation. Sublytic MAC deposition can induce astrocytes to release pro-inflammatory cytokines and chemokines, further enhancing immune cell recruitment (Papadopoulos & Verkman, 2012). Additionally, complement activation products such as C3a and C5a act as anaphylatoxins, promoting vascular permeability and leukocyte activation, thereby perpetuating the inflammatory cycle.

4.3 Effector Mechanisms

Neutrophil and Eosinophil Recruitment

Complement activation leads to robust recruitment of neutrophils and eosinophils, which are characteristic features of NMOSD lesions. C5a acts as a potent chemoattractant, guiding these granulocytes to sites of astrocyte injury (Saadoun et al., 2012).

• Neutrophils contribute to tissue damage via release of proteases, reactive oxygen species (ROS), and neutrophil extracellular traps (NETs).
• Eosinophils, uniquely abundant in NMOSD, release cytotoxic granules (e.g., major basic protein), exacerbating astrocyte and endothelial injury.

This granulocytic infiltration distinguishes NMOSD from multiple sclerosis, where lymphocytic infiltration predominates.

Cytokine Storm (IL-6, IL-17, TNF-α)

Complement activation is closely linked with the induction of a pro-inflammatory cytokine milieu, often referred to as a cytokine storm. Key cytokines include:

• Interleukin-6 (IL-6): Promotes B-cell differentiation, plasmablast survival, and BBB disruption (Chihara et al., 2011).
• Interleukin-17 (IL-17): Enhances neutrophil recruitment and increases BBB permeability (Kebir et al., 2007).
• Tumor necrosis factor-alpha (TNF-α): Contributes to endothelial activation and amplifies inflammatory signaling.

These cytokines synergistically sustain neuroinflammation, facilitate immune cell infiltration, and exacerbate tissue injury, creating a self-perpetuating inflammatory loop.

Table 3. Complement-Mediated Mechanisms in NMOSD

Figure 3. Complement-Mediated Neuroinflammatory Cascade in NMOSD

5. Molecular and Immunological Biomarkers in Neuromyelitis Optica Spectrum Disorder (NMOSD)

Biomarkers play a critical role in the diagnosis, disease monitoring, prognosis, and therapeutic stratification of NMOSD. Given the heterogeneity of clinical presentations and overlapping features with other demyelinating disorders, the identification of specific molecular and immunological markers has significantly improved diagnostic accuracy and mechanistic understanding. These biomarkers can be broadly categorized into diagnostic, inflammatory, neurodegenerative, and emerging molecular signatures.

5.1 Diagnostic Biomarkers

AQP4-IgG (Gold Standard)

Aquaporin-4 immunoglobulin G (AQP4-IgG) is the most specific and sensitive biomarker for NMOSD and is considered the diagnostic gold standard. Detected ??????? cell-based assays, AQP4-IgG demonstrates high specificity (>99%) and sensitivity (~70–80%) for NMOSD (Lennon et al., 2004; Waters et al., 2012). These antibodies target extracellular epitopes of AQP4 on astrocytic endfeet, directly mediating complement activation and astrocyte injury. The presence of AQP4-IgG not only confirms diagnosis but also predicts a relapsing disease course and guides immunotherapy decisions.

MOG-IgG (Differential Diagnosis)

Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) are detected in a subset of patients with demyelinating disorders who are negative for AQP4-IgG. MOG-IgG-associated disease (MOGAD) represents a distinct clinical entity, characterized by different pathophysiology, imaging features, and treatment responses (Reindl & Waters, 2019). Unlike NMOSD, MOGAD primarily targets oligodendrocytes rather than astrocytes. Therefore, testing for MOG-IgG is essential for differential diagnosis in seronegative NMOSD cases.

5.2 Inflammatory Biomarkers

Cytokines: IL-6, IL-17, CXCL13

Pro-inflammatory cytokines serve as important indicators of disease activity and immune dysregulation in NMOSD:

• Interleukin-6 (IL-6): A central mediator that promotes B-cell differentiation, plasmablast survival, and AQP4-IgG production. Elevated IL-6 levels in serum and cerebrospinal fluid (CSF) correlate with disease relapses (Chihara et al., 2011).
• Interleukin-17 (IL-17): Produced by Th17 cells, IL-17 enhances BBB permeability and recruits neutrophils, contributing to neuroinflammation (Kebir et al., 2007).
• CXCL13: A B-cell chemoattractant involved in lymphoid follicle formation; increased levels indicate active B-cell recruitment and intrathecal inflammation (Pietroboni et al., 2020).

Complement Proteins (C3, C5b-9)

Complement components are important biomarkers reflecting ongoing immune-mediated astrocyte injury:

• C3: Elevated levels indicate activation of the complement cascade and systemic inflammation.
• C5b-9 (Membrane Attack Complex): Detection of soluble C5b-9 in serum or CSF reflects terminal complement activation and correlates with disease severity (Lucchinetti et al., 2014).

These markers provide insights into complement-mediated neuroinflammation and may guide the use of complement-targeting therapies.

5.3 Neurodegeneration Markers

Neurofilament Light Chain (NfL)

Neurofilament light chain (NfL) is a sensitive biomarker of axonal injury and neurodegeneration. Elevated NfL levels in serum and CSF are associated with acute relapses, lesion burden, and long-term disability in NMOSD (Bjornevik et al., 2020). NfL serves as a prognostic indicator and may be used to monitor treatment response.

Glial Fibrillary Acidic Protein (GFAP)

Glial fibrillary acidic protein (GFAP) is a cytoskeletal protein specific to astrocytes and a key marker of astrocyte injury. Elevated GFAP levels, particularly during acute attacks, strongly correlate with disease activity and severity (Takano et al., 2010). GFAP is considered more specific than NfL for NMOSD due to its direct association with astrocytopathy.

5.4 Emerging Biomarkers

MicroRNAs (miRNAs)

MicroRNAs are small non-coding RNAs that regulate gene expression and immune responses. Dysregulated expression of specific miRNAs (e.g., miR-21, miR-155) has been reported in NMOSD, influencing inflammatory pathways and B-cell activation (Jiang et al., 2014). These molecules hold promise as non-invasive diagnostic and prognostic biomarkers.

Exosomal Proteins

Exosomes are extracellular vesicles that carry proteins, lipids, and nucleic acids reflective of their cellular origin. In NMOSD, exosomal cargo derived from astrocytes and immune cells contains disease-specific signatures, including inflammatory mediators and autoantigens (Wang et al., 2020). Exosomal biomarkers offer advantages in stability and accessibility, making them attractive candidates for liquid biopsy approaches.

Table 4. Molecular and Immunological Biomarkers in NMOSD

6. Advanced Neuroimaging in Neuromyelitis Optica Spectrum Disorder (NMOSD)

Advanced neuroimaging plays a pivotal role in the diagnosis, disease monitoring, and mechanistic understanding of NMOSD. Imaging modalities not only help differentiate NMOSD from other demyelinating disorders such as multiple sclerosis but also provide insights into astrocytopathy, axonal injury, and neuroinflammation. Conventional magnetic resonance imaging (MRI) remains the cornerstone, while advanced imaging techniques and emerging molecular imaging approaches are enhancing diagnostic precision and prognostic evaluation (Wingerchuk et al., 2015; Kim et al., 2015).

6.1 Magnetic Resonance Imaging (MRI)

Longitudinally Extensive Transverse Myelitis (LETM)

One of the hallmark imaging features of NMOSD is longitudinally extensive transverse myelitis (LETM), defined as spinal cord lesions extending over three or more contiguous vertebral segments. These lesions typically involve the central gray matter and may cause cord swelling during acute phases (Wingerchuk et al., 2015). LETM lesions often show T2 hyperintensity and variable contrast enhancement, reflecting active inflammation and BBB disruption. Chronic stages may demonstrate cord atrophy, correlating with permanent disability.

Optic Nerve Lesions

Optic neuritis in NMOSD is characterized by long-segment, often bilateral involvement of the optic nerves, frequently extending to the optic chiasm and optic tracts (Petzold et al., 2014). MRI typically reveals T2 hyperintensity and gadolinium enhancement, indicating active inflammation. Compared to multiple sclerosis, NMOSD-associated optic neuritis is more severe and associated with poorer visual outcomes.

Brainstem Involvement

Brainstem lesions are commonly observed in NMOSD, particularly in regions with high AQP4 expression such as the area postrema. Lesions in this region may present clinically with intractable nausea, vomiting, and hiccups (Apiwattanakul et al., 2010). MRI findings include T2 hyperintense lesions in the dorsal medulla, periependymal regions, and hypothalamus. These lesions are often reversible with treatment but may recur during relapses.

6.2 Advanced MRI Techniques

Diffusion Tensor Imaging (DTI)

Diffusion tensor imaging (DTI) is an advanced MRI modality that assesses white matter microstructural integrity by measuring water diffusion properties. In NMOSD, DTI reveals reduced fractional anisotropy (FA) and increased mean diffusivity (MD), indicating axonal damage and demyelination, even in normal-appearing white matter (Ciccarelli et al., 2003). DTI is particularly useful in detecting subclinical injury and evaluating disease progression.

Magnetization Transfer Imaging (MTI)

Magnetization transfer imaging (MTI) provides insights into myelin integrity by measuring the exchange of magnetization between free water and macromolecules. Reduced magnetization transfer ratio (MTR) values in NMOSD lesions indicate myelin loss and tissue destruction (Rovira et al., 2015). MTI can differentiate NMOSD from multiple sclerosis, as NMOSD lesions often show more severe tissue damage with less diffuse white matter involvement.

6.3 Optical Coherence Tomography (OCT)

Retinal Nerve Fiber Layer (RNFL) Thinning

Optical coherence tomography (OCT) is a non-invasive imaging technique that provides high-resolution cross-sectional images of the retina. In NMOSD, OCT demonstrates significant retinal nerve fiber layer (RNFL) thinning, reflecting axonal loss and optic neuritis (Petzold et al., 2010). RNFL thinning is often more severe than in multiple sclerosis and correlates with visual impairment.

Ganglion Cell Loss

In addition to RNFL thinning, NMOSD patients exhibit loss of retinal ganglion cells, particularly in the ganglion cell–inner plexiform layer (GCIPL). This reflects retrograde degeneration of optic nerve damage and serves as a marker of neurodegeneration (Green et al., 2013). OCT-derived metrics are increasingly used as surrogate endpoints in clinical trials.

6.4 PET Imaging and Molecular Imaging

Neuroinflammation Visualization

Positron emission tomography (PET) enables in vivo visualization of neuroinflammatory processes using radioligands that bind to activated immune cells. PET imaging can detect areas of active inflammation that may not be visible on conventional MRI, providing additional diagnostic and research insights (Rissanen et al., 2014).

Microglial Activation

PET tracers targeting the translocator protein (TSPO), such as [¹¹C]-PK11195, are used to assess microglial activation, a key component of neuroinflammation. Increased TSPO binding in NMOSD lesions indicates activation of innate immune responses and correlates with disease activity (Datta et al., 2017). Molecular imaging thus offers a promising avenue for understanding disease mechanisms and evaluating therapeutic responses.

Table 5. Neuroimaging Modalities and Findings in NMOSD

Figure 5. Neuroimaging Spectrum in NMOSD

7. Monoclonal Antibody-Based Therapeutic Strategies in Neuromyelitis Optica Spectrum Disorder (NMOSD)

The advent of monoclonal antibody (mAb)-based therapies has transformed the therapeutic landscape of NMOSD, shifting management from broad immunosuppression to targeted immunomodulation. These biologics are designed to interfere with key immunopathogenic mechanisms, including B-cell activation, cytokine signaling, and complement-mediated injury. Clinical trials have demonstrated significant reductions in relapse rates and improved long-term outcomes with these agents (Cree et al., 2019; Pittock et al., 2019).

7.1 Anti-CD20 Therapies

Rituximab and Ocrelizumab

Anti-CD20 monoclonal antibodies, such as rituximab and ocrelizumab, target the CD20 antigen expressed on pre-B and mature B lymphocytes. Rituximab, a chimeric monoclonal antibody, has been widely used off-label in NMOSD, while ocrelizumab, a humanized antibody, offers improved tolerability and reduced immunogenicity (Hauser et al., 2017).

B-Cell Depletion Mechanisms

These agents mediate B-cell depletion through:

• Complement-dependent cytotoxicity (CDC)
• Antibody-dependent cellular cytotoxicity (ADCC)
• Induction of apoptosis

By depleting circulating B cells, anti-CD20 therapies reduce AQP4-IgG production, limit antigen presentation, and suppress pro-inflammatory cytokine release. Clinical studies have shown substantial reductions in relapse frequency and stabilization of disability (Kim et al., 2013).

7.2 Anti-IL-6 Receptor Therapies

Tocilizumab and Satralizumab

Interleukin-6 (IL-6) plays a central role in NMOSD pathogenesis by promoting B-cell differentiation, plasmablast survival, and BBB disruption. Tocilizumab, a humanized anti-IL-6 receptor antibody, and satralizumab, a newer engineered antibody with extended half-life, block IL-6 signaling pathways (Yamamura et al., 2019).

Modulation of Cytokine Signaling

IL-6 receptor blockade results in:

• Reduced plasmablast survival and AQP4-IgG production
• Decreased BBB permeability
• Suppression of Th17-mediated inflammation

Clinical trials (e.g., SAkuraSky and SAkuraStar) have demonstrated that satralizumab significantly reduces relapse risk, particularly in AQP4-IgG seropositive patients (Yamamura et al., 2019). Tocilizumab has also shown efficacy in refractory NMOSD cases.

7.3 Complement Inhibitors

Eculizumab (C5 Inhibitor)

Eculizumab is a humanized monoclonal antibody that binds to complement protein C5, preventing its cleavage into C5a and C5b. This inhibits formation of the membrane attack complex (MAC), thereby preventing complement-mediated astrocyte lysis (Pittock et al., 2019).

Ravulizumab

Ravulizumab, a long-acting derivative of eculizumab, offers sustained complement inhibition with less frequent dosing. Both agents are particularly effective in AQP4-IgG-positive NMOSD, where complement activation is a main pathogenic mechanism.

7.4 Emerging Biologics

Inebilizumab (Anti-CD19)

Inebilizumab targets CD19, a broader B-cell marker expressed on a wider range of B-cell lineage cells, including plasmablasts and some plasma cells. This allows more comprehensive depletion of antibody-producing cells compared to CD20-targeted therapies (Cree et al., 2019). Clinical trials have shown significant reductions in relapse rates and disease activity.

Novel Fc-Engineered Antibodies

Emerging biologics include Fc-engineered antibodies designed to enhance effector functions such as ADCC while minimizing immunogenicity. These next-generation antibodies aim to improve efficacy, reduce dosing frequency, and enhance safety profiles. Additionally, therapies targeting other immune pathways (e.g., complement regulators, cytokine inhibitors) are under active investigation.

7.5 Comparative Efficacy and Safety

Relapse Reduction

Monoclonal antibody therapies have demonstrated remarkable efficacy in reducing relapse rates:

• Eculizumab: ~94% relapse risk reduction in clinical trials (Pittock et al., 2019)
• Inebilizumab: Significant reduction in attack risk (~73%) (Cree et al., 2019)
• Satralizumab: Reduced relapse rates, especially in seropositive patients (Yamamura et al., 2019)
• Rituximab: Substantial real-world efficacy in relapse prevention

These agents have shifted NMOSD from a highly disabling disease to a more manageable chronic condition.

Adverse Effects and Infection Risk

Despite their efficacy, monoclonal antibodies are associated with potential adverse effects:

• Infection risk: Particularly with complement inhibitors (e.g., meningococcal infections with eculizumab)
• Infusion-related reactions: Common with rituximab and ocrelizumab
• Hematological effects: Neutropenia, hypogammaglobulinemia
• Long-term immunosuppression risks

Vaccination (e.g., meningococcal vaccine prior to eculizumab therapy) and careful monitoring are essential to mitigate these risks.

Table 6. Monoclonal Antibody Therapies in NMOSD